Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) is a biopharmaceutical company that focuses on developing antibody-based treatments for cancer. The company is known for DANYELZA, a monoclonal antibody used to treat pediatric patients with high-risk neuroblastoma. Y-mAbs is also working on other treatments that are in various stages of clinical trials.
Over the past year, the consensus price target for YMAB has decreased from $10.57 to $8.60. This suggests that analysts have become more cautious about the company's stock price. However, the price target has remained steady at $8.60 over the last month and quarter, indicating no major changes in analysts' outlook recently.
Despite the decrease in the consensus price target, YMAB's stock price surged by 103.3% in a recent trading session, with trading volume exceeding average levels. This significant increase reflects a positive market reaction, although current earnings estimate revisions suggest that further price increases may not occur in the near term.
Analyst Etzer Darout from BMO Capital has set a higher price target of $26 for YMAB, indicating a more optimistic outlook. Additionally, the company has been upgraded to a Zacks Rank #2 (Buy), which suggests increased confidence in its earnings potential and could lead to a rise in the stock's price.
Investors should monitor Y-mAbs Therapeutics' progress in clinical trials and potential market approvals, as these developments could significantly impact the company's stock performance and analysts' future price targets. Recent company news and updates, such as the Q1 2025 earnings call, provide valuable insights into the company's strategic direction and financial health.
